Boston Scientific (BSX) reports $5.4B Q2 revenue with 7.5% growth

Boston Scientific reported Q2 revenues of $5.4 billion, reflecting a 7.5% year-over-year increase. The cardiovascular segment drove most of this revenue, generating about $3.6 billion, up 8.3% YoY. However, the company has lowered its 2026 earnings per share outlook to between $3.28 and $3.32, down from earlier expectations. Following the announcement, Boston's stock price fell by over 5% to $42.67 on July 29. This adjustment in outlook may indicate potential challenges in future growth, which is important for investors to consider.